Literature DB >> 7489996

Bystander effect caused by suicide gene expression indicates the feasibility of gene therapy for hepatocellular carcinoma.

S Kuriyama1, T Nakatani, K Masui, T Sakamoto, K Tominaga, M Yoshikawa, H Fukui, K Ikenaka, T Tsujii.   

Abstract

In the field of gene therapy using retroviral vectors, it appears impossible to introduce a foreign gene into all target cells. Therefore adjacent cell killing, the socalled bystander effect, caused by genetically modified cells provides therapeutic advantages for gene therapy against cancers. We retrovirally transduced the herpes simplex virus thymidine kinase (HSV-tk) gene into murine and rat hepatocellular carcinoma (HCC) cells. These HSV-tk gene-transduced HCC cells were cocultured with the corresponding parental cells in the presence of ganciclovir, at a concentration not at all cytotoxic to the parental cells. When parental HCC cells were cocultured with their HSV-tk gene-transduced counterparts at a high density at which most cells were in contact with one another, they were markedly eliminated. Conversely, when cocultured at a low density at which none of the cells were in contact, a weak but statistically significant bystander effect was observed. Addition of lysates of HSV-tk gene-transduced cells in the presence of ganciclovir did not cause and killing of parental cells. Furthermore, media conditioned by transduced cells with ganciclovir exhibited weak cytotoxic effects on parental cells. These results indicate that cell-cell contact plays a major causative role in the bystander effect and that minor contributors to this phenomenon are some cytotoxic substance released from transduced cells. Importantly, the bystander effect was induced in vivo as well as in vitro. When mixtures of transduced and untransduced HCC cells were implanted into the flank region of mice, intraperitoneal ganciclovir administration considerably inhibited tumor development, indicating the feasibility of gene therapy with HSV-tk gene and ganciclovir against HCC.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7489996

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  7 in total

Review 1.  Methods for gene transfer to the central nervous system.

Authors:  Boris Kantor; Rachel M Bailey; Keon Wimberly; Sahana N Kalburgi; Steven J Gray
Journal:  Adv Genet       Date:  2014       Impact factor: 1.944

2.  Gene therapy of HSV-TK transferred by the EBV based expression vector on experimental hepatocellular carcinoma.

Authors:  Q Ding; Z Wu; X Chen; A H Musa; J Hu; Y Zhan
Journal:  J Tongji Med Univ       Date:  2001

3.  Assessment of efficiency and safety of adenovirus mediated gene transfer into normal and damaged murine livers.

Authors:  T Nakatani; S Kuriyama; K Tominaga; T Tsujimoto; A Mitoro; M Yamazaki; H Tsujinoue; H Yoshiji; S Nagao; H Fukui
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

4.  Electrochemotherapy for colorectal cancer with commonly used chemotherapeutic agents in a mouse model.

Authors:  S Kuriyama; M Matsumoto; A Mitoro; H Tsujinoue; T Nakatani; H Fukui; T Tsujii
Journal:  Dig Dis Sci       Date:  2000-08       Impact factor: 3.199

5.  Membrane-bound alkaline phosphatase gene induces antitumor effect by G2/M arrest in etoposide phosphate-treated cancer cells.

Authors:  Kye Young Kim; Young Joo Cho; Geoung A Jeon; Pan Dong Ryu; Jin Nam Myeong
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

Review 6.  Current Status of Gene Therapy in Hepatocellular Carcinoma.

Authors:  Saranya Chidambaranathan Reghupaty; Devanand Sarkar
Journal:  Cancers (Basel)       Date:  2019-08-28       Impact factor: 6.639

7.  Depletion of T cells via Inducible Caspase 9 Increases Safety of Adoptive T-Cell Therapy Against Chronic Hepatitis B.

Authors:  Alexandre Klopp; Sophia Schreiber; Anna D Kosinska; Martin Pulé; Ulrike Protzer; Karin Wisskirchen
Journal:  Front Immunol       Date:  2021-10-06       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.